Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
ADRs Advance; Connect Biopharma Holdings Climbs 19%
Kangnai De Life Science (CNTB.US) is trapped on the eve of commercialization: the founder left and the stock price fell more than 30% in seven days.
On June 21st, the stock price of Kangnaide Biotechnology (CNTB.US) fell by 3.95%. This is the seventh trading day since its Chinese founding team completely left the company, and also the seventh trading day of the company's new round of stock price decline. During this period, the company's stock price has accumulated a 31.86% decline.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Connect Biopharma Hldgs Analyst Ratings
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $8
Express News | Connect Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Connect Biopharma: Zheng Wei Will Remain on Board and Serve as Adviser to Assist With Transition >CNTB
Connect Biopharma: David Szekeres Appointed as Pres >CNTB
Express News | Connect Biopharma Holdings Ltd - Appoints Kleanthis G. Xanthopoulos as New Chair of Board of Directors
Express News | Connect Biopharma Holdings Ltd - Appoints Barry Quart as Chief Executive Officer (CEO) and Director
Press Release: Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Connect Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) Top Owners Are Private Equity Firms With 39% Stake, While 22% Is Held by Insiders
Express News | Connect Biopharma Presents Abstract About Results From Rademikibart Global Phase 2b Trial In Patients With Moderate-to-severe Asthma At ATS 2024 International Conference
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data From Its Global Phase 2b in Patients With Moderate-to-Severe Asthma
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma